Department of Ophthalmology, The Second Hospital of Dalian Medical University, 467 Zhongshan Road, Shahekou District, Dalian, China.
Int Ophthalmol. 2021 Sep;41(9):2963-2971. doi: 10.1007/s10792-021-01855-5. Epub 2021 May 5.
To compare the changes in subfoveal choroidal thickness (SFChT) in myopic children treated with 0.01% atropine, orthokeratology (OK), or their combination in myopic children, and to study the connection between increase in SFChT and axial length (AL) elongation.
This is a prospective, randomized, controlled study. A total of 67 children were included; 22 patients were randomly assigned to the SA group (patients with spectacles and 0.01% atropine), 24 patients were randomly assigned to the OK group (OK), and 21 patients were randomly assigned to the OKA group (OK and 0.01% atropine). Comprehensive ophthalmologic examinations were performed at baseline, 1 month, 6 months, and 12 months.
After 1 month, SFChT increased by 5.41 ± 1.65 μm in the SA group, 17.46 ± 2.79 μm in the OK group, and 20.19 ± 2.18 μm in the OKA group (P = 0.00), whereas AL was not significantly increased. After 12 months, the changes of SFChT were not increased significantly compared with that at 1 month; AL increased by 0.20 ± 0.03 mm in the SA group, 0.28 ± 0.03 mm in the OK group, and 0.14 ± 0.03 mm in the OKA group (P = 0.00). The change in SFChT at 12 month was negatively correlated with the change in AL at 12 months.
The control of AL elongation was better in SA group than OK group. The increase in SFChT was best in OKA group, followed by OK group, and the changes were significant after only 1 month. In addition, the increase in SFChT may influence AL elongation and myopia progression.
比较 0.01%阿托品、角膜塑形术（orthokeratology，OK）或两者联合治疗近视儿童的眼底部脉络膜厚度（subfoveal choroidal thickness，SFChT）的变化，并研究 SFChT 增加与眼轴（axial length，AL）伸长之间的关系。
这是一项前瞻性、随机、对照研究。共纳入 67 例儿童，22 例患者随机分为 SA 组（戴眼镜和 0.01%阿托品），24 例患者随机分为 OK 组（OK），21 例患者随机分为 OKA 组（OK 和 0.01%阿托品）。在基线、1 个月、6 个月和 12 个月时进行全面眼科检查。
1 个月后，SA 组 SFChT 增加 5.41±1.65μm，OK 组增加 17.46±2.79μm，OKA 组增加 20.19±2.18μm（P=0.00），而 AL 无明显增加。12 个月后，SFChT 的变化与 1 个月时相比无明显增加；SA 组 AL 增加 0.20±0.03mm，OK 组增加 0.28±0.03mm，OKA 组增加 0.14±0.03mm（P=0.00）。12 个月时 SFChT 的变化与 12 个月时 AL 的变化呈负相关。
与 OK 组相比，SA 组控制 AL 伸长更好。OKA 组 SFChT 增加最好，其次是 OK 组，仅 1 个月后变化明显。此外，SFChT 的增加可能会影响 AL 伸长和近视进展。
